Lundbeck CEO Ulf Wiinberg Steps Down After Breaching Code Of Conduct
This article was originally published in The Pink Sheet Daily
Executive Summary
Candidates for the post in the Danish biotech are likely to have a commercial background, as Wiinberg-inspired strategy of geographic expansion and a growing a pipeline of CNS products continues to bear fruit.
You may also be interested in...
Kare Schultz Becomes Lundbeck’s CEO As New Launches Gather Pace
One of the first priorities for Lundbeck’s new chief executive will be supporting new product launches worldwide to boost the Danish company’s geographic and product diversification.
Sanofi Board Forces CEO Chris Viehbacher to Resign Amid Lantus Woes
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
Lundbeck Cuts 150 R&D Jobs To Control Costs Ahead Of Key Patent Expiry
Danish pharma increases investment in new product launches as it prepares for loss of patent protection on its lead product, escitalopram.